Fortrea Holdings/$FTRE
1D1W1MYTD1Y5YMAX
Capital at risk
About Fortrea Holdings
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
- Ticker
- $FTRE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 14,000
- Headquarters
- Durham, United States
- Website
- www.fortrea.com
Fortrea Holdings Metrics
BasicAdvanced
$1.9B
-
-$0.92
1.95
-
Price and volume
Market cap
$1.9B
Beta
1.95
52-week high
$21.39
52-week low
$8.31
Average daily volume
1.4M
Financial strength
Current ratio
0.958
Quick ratio
0.854
Long term debt to equity
2.082
Total debt to equity
2.132
Interest coverage (TTM)
0.31%
Profitability
EBITDA (TTM)
98.3
Gross margin (TTM)
19.30%
Net profit margin (TTM)
-3.18%
Operating margin (TTM)
0.97%
Effective tax rate (TTM)
-9.51%
Revenue per employee (TTM)
$190,000
Management effectiveness
Return on assets (TTM)
0.58%
Return on equity (TTM)
-15.30%
Valuation
Price to revenue (TTM)
0.696
Price to book
3.63
Price to tangible book (TTM)
-1.88
Price to free cash flow (TTM)
9.51
Free cash flow yield (TTM)
10.52%
Free cash flow per share (TTM)
2.105
Growth
Revenue change (TTM)
-2.09%
Earnings per share change (TTM)
-91.94%
3-year revenue growth (CAGR)
-3.11%
3-year earnings per share growth (CAGR)
-16.04%
What the Analysts think about Fortrea Holdings
Analyst ratings (Buy, Hold, Sell) for Fortrea Holdings stock.
Analyst projections of the future price of Fortrea Holdings stock.
Bulls say / Bears say
Commercial momentum is improving: Fortrea reported four consecutive quarters with book-to-bill above 1.0x, while first-half net new business awards rose 19% year on year. It also raised 2026 revenue and adjusted EBITDA guidance, suggesting management sees the recent bookings converting into better results. (GlobeNewswire, StockAnalysis)
The cost-reduction plan is lifting profitability even before revenue recovers. Second-quarter adjusted EBITDA rose to $58.7 million from $54.9 million and free cash flow was $19.9 million, helping the company raise its full-year adjusted EBITDA target to $205 million-$220 million. (GlobeNewswire, StockAnalysis)
Fortrea is strengthening its early-stage offering by agreeing to buy Worldwide Clinical Trials’ Early Phase Services division for about $45 million. The deal would add a 200-bed clinical pharmacology unit and a bioanalytical laboratory, giving Fortrea a more integrated Phase I-IV platform if approvals and the transition proceed smoothly. (GlobeNewswire)
Revenue recovery is still unproven. Second-quarter revenue fell 4.5% year on year to $678.2 million, with management citing lower pass-through costs and continued functional-service-provider headwinds; first-half revenue also declined. (GlobeNewswire, StockAnalysis)
Reported profitability remains weak despite better adjusted figures. Fortrea still posted a $13.2 million GAAP net loss in the second quarter, so investors must decide whether the improvement in adjusted earnings reflects durable operating progress rather than a temporary benefit from cost cuts and mix. (GlobeNewswire)
The proposed acquisition brings execution and capital-allocation risk before its benefits are demonstrated. It is an all-cash purchase that remains subject to regulatory and licence approvals, and Fortrea has not disclosed a revenue or earnings contribution for the acquired operations. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 24 Sept 2026.
Fortrea Holdings Financial Performance
Revenues and expenses
Fortrea Holdings Earnings Performance
Company profitability
Upcoming events
No upcoming events
Fortrea Holdings News
AllArticlesVideos
Fortrea Leverages Early Phase Strengths to Accelerate Market Expansion
Benzinga3 weeks ago
Fortrea Q2 Earnings Call Highlights
MarketBeat2 months ago
Kaskela Law Firm Announces Investigation of Fortrea Holdings Inc. (FTRE) and Encourages Long-Term FTRE Shareholders with Investment Losses to Contact the Firm
Business Wire2 months ago
Funds containing Fortrea Holdings
AllUSDEURGBP
Fund name | Fund size | $FTRE weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.19% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.19% |
iShares Healthcare Innovation£DRDR | £1B | 0.19% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.12% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.12% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.